Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Germany
/
Healthcare
Create a narrative
Eckert & Ziegler Community
XTRA:EUZ Community
1
Narratives
written by author
0
Comments
on narratives written by author
13
Fair Values set
on narratives written by author
Create a narrative
Eckert & Ziegler
Latest
Undervalued
Overvalued
Community Investing Ideas
Eckert & Ziegler
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
Lutetium-177 Approval And Actinium Production Will Expand Radioisotope Markets
Key Takeaways European approval of Lutetium-177 and actinium production expansion are poised to boost revenue and product availability in new markets. Strategic partnerships and reduced production delays are expected to improve EBIT margins and stabilize revenue growth.
View narrative
€66.00
FV
1.8% undervalued
intrinsic discount
7.79%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
9
users have followed this narrative
6 days ago
author updated this narrative
Your Valuation for
EUZ
EUZ
Eckert & Ziegler
Your Fair Value
€
Current Price
€64.80
9.4% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
428m
2015
2018
2021
2024
2025
2027
2030
Revenue €427.5m
Earnings €58.7m
Advanced
Set Fair Value